Company intelligence / Profile preview

RetroSense Therapeutics

Ann Arbor, Michigan, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~2
Development stage: Phase 1

Overview

RetroSense’s lead program, RST‑001, entered clinical trials targeting retinitis pigmentosa. The approach aimed to restore some vision in patients with severe loss due to degeneration of retinal photoreceptors. The company was acquired before late-stage or commercial results were available.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (specifically optogenetics-based gene therapy)
Industry: Biotech

Drug pipeline

1 asset

RST-001

Phase 1

Indications: Retinitis pigmentosa

Partnerships

Wayne State University for foundational research and technology licensing

Beyond the preview

Go deeper on RetroSense Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetroSense Therapeutics.

Explore the full profile